RSV604 (Synonyms: A-60444)

目录号: HY-12993 纯度: 99.92%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

RSV604 (A-60444) 是呼吸道合胞病毒 (RSV) 复制的抑制剂。RSV604 靶向核衣壳蛋白，K_d 值为 1.6 μM。RSV604 表现出针对 RSV A 和 B 亚型的众多临床分离株的亚微摩尔活性 (平均 EC₅₀=0.8 μM)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

RSV604 Chemical Structure

CAS No. : 676128-63-5

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
Free Sample (0.1 - 0.2 mg)		Apply now
10 mM * 1 mL in DMSO	￥660	In-stock
5 mg	￥600	In-stock
10 mg	￥990	In-stock
50 mg	￥3280	In-stock
100 mg	￥5250	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of RSV604:

RSV604 racemate In-stock
RSV604 (R enantiomer) 询价

MCE 顾客使用本产品发表的 2 篇科研文献

RSV604 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a K_d of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC₅₀s=0.8 μM)^[1]^[2].

IC₅₀ & Target

Kd: 1.6 μM (nucleocapsid protein)^[2]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
HEp-2	EC₅₀	> 20 μM Compound: RSV604	Antiviral activity against RSV RSS with N protein I129L plus L139I mutant mutation in human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS with N protein I129L plus L139I mutant mutation in human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	CC₅₀	> 50 μM Compound: RSV604	Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	> 50 μM Compound: RSV604	Antiviral activity against Pneumonia virus of mice 15 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against Pneumonia virus of mice 15 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	> 50 μM Compound: RSV604	Antiviral activity against Parainfluenza virus type 1 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against Parainfluenza virus type 1 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	> 50 μM Compound: RSV604	Antiviral activity against Parainfluenza virus type 3 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against Parainfluenza virus type 3 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	> 50 μM Compound: RSV604	Antiviral activity against human Metapneumovirus infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against human Metapneumovirus infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.3 μM Compound: RSV604	Antiviral activity against bovine RSV snook infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against bovine RSV snook infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.5 μM Compound: RSV604	Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.6 μM Compound: RSV604	Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.6 μM Compound: RSV604	Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	IC₅₀	0.7 μM Compound: 17b, RSV-604	Antiviral activity against RSV RSS in Hep2 cells by plaque assay Antiviral activity against RSV RSS in Hep2 cells by plaque assay	[PMID: 17341059]
HEp-2	EC₅₀	0.8 μM Compound: RSV604	Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.8 μM Compound: RSV604	Antiviral activity against RSV A isolates infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV A isolates infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.8 μM Compound: RSV604	Antiviral activity against RSV B isolates infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV B isolates infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	0.86 μM Compound: RSV604	Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	[PMID: 17576833]
HEp-2	IC₅₀	0.9 μM Compound: 17b, RSV-604	Antiviral activity against RSV RSS in Hep2 cells by XTT assay Antiviral activity against RSV RSS in Hep2 cells by XTT assay	[PMID: 17341059]
HEp-2	EC₅₀	0.9 μM Compound: RSV604	Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	1.14 μM Compound: RSV604	Antiviral activity against RSV RSS M2 mutant infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS M2 mutant infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	IC₅₀	1.4 μM Compound: 17b, RSV-604	Antiviral activity against RSV RSS in Hep2 cells by ELISA Antiviral activity against RSV RSS in Hep2 cells by ELISA	[PMID: 17341059]
HEp-2	EC₅₀	1.4 μM Compound: RSV604	Antiviral activity against 0.02 MOI RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay Antiviral activity against 0.02 MOI RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	1.7 μM Compound: RSV604	Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA	[PMID: 17576833]
HEp-2	EC₅₀	2.55 μM Compound: RSV604	Antiviral activity against 1.5 MOI RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay Antiviral activity against 1.5 MOI RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	2.7 μM Compound: RSV604	Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	30.4 μM Compound: RSV604	Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	4.78 μM Compound: RSV604	Antiviral activity against RSV RSS with N protein N105D mutation in human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS with N protein N105D mutation in human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	6.03 μM Compound: RSV604	Antiviral activity against RSV RSS with N protein I120L mutation in human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS with N protein I120L mutation in human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	6.7 μM Compound: RSV604	Antiviral activity against RSV RSS with N protein L139I mutation in human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS with N protein L139I mutation in human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]

体外研究
(In Vitro)

RSV604 (5 天) 抑制四种实验室 RSV 菌株 (RSS、Long、A2 和 B) 的生长，在噬菌斑减少试验中，EC₅₀ 范围为 0.5 至 0.9 μM^[1]。
RSV604 (6 天) 抑制 RSV 诱导的 HEp-2 细胞死亡，EC₅₀ 为 0.86 μM^[1]。
RSV604 (3 天) 减少 RSV 感染的 HEp-2 细胞中的病毒抗原合成，EC₅₀ 为 1.7 μM^[1]。
RSV604 (1-20 μM；7 天) 以剂量依赖性方式抑制人气道上皮 (HAE) 细胞中的 RSV 感染，没有明显的细胞毒性、基底外侧液体渗漏到顶端表面或改变纤毛摆动频率^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

388.39

Formula

C₂₂H₁₇FN₄O₂

CAS 号

676128-63-5

性状

固体

颜色

White to off-white

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (257.47 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5747 mL	12.8737 mL	25.7473 mL
5 mM	0.5149 mL	2.5747 mL	5.1495 mL
10 mM	0.2575 mL	1.2874 mL	2.5747 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.44 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.44 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.44 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.92%

选择批次：

Data Sheet (648 KB) SDS (252 KB)

COA (296 KB) RP-HPLC (275 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Chapman J, et al. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother. 2007 Sep;51(9):3346-53. [Content Brief]

[2]. Challa S, et al. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7. [Content Brief]

RSV604 相关分类

Infection

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5747 mL	12.8737 mL	25.7473 mL	64.3683 mL
	5 mM	0.5149 mL	2.5747 mL	5.1495 mL	12.8737 mL
	10 mM	0.2575 mL	1.2874 mL	2.5747 mL	6.4368 mL
	15 mM	0.1716 mL	0.8582 mL	1.7165 mL	4.2912 mL
	20 mM	0.1287 mL	0.6437 mL	1.2874 mL	3.2184 mL
	25 mM	0.1030 mL	0.5149 mL	1.0299 mL	2.5747 mL
	30 mM	0.0858 mL	0.4291 mL	0.8582 mL	2.1456 mL
	40 mM	0.0644 mL	0.3218 mL	0.6437 mL	1.6092 mL
	50 mM	0.0515 mL	0.2575 mL	0.5149 mL	1.2874 mL
	60 mM	0.0429 mL	0.2146 mL	0.4291 mL	1.0728 mL
	80 mM	0.0322 mL	0.1609 mL	0.3218 mL	0.8046 mL
	100 mM	0.0257 mL	0.1287 mL	0.2575 mL	0.6437 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

RSV604676128-63-5A-60444RSV 604RSV-604A60444A 60444RSVRespiratory syncytial virusrespiratorysyncytialvirusnucleocapsidproteinInhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

RSV604 (Synonyms: A-60444)

Customer Review

Other Forms of RSV604:

MCE 顾客使用本产品发表的 2 篇科研文献